Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Merck Sharp & Dohme LLC | INDUSTRY |
| Center for Primary Care and Public Health (Unisante), University of Lausanne, Switzerland | OTHER |
Not provided
Not provided
Not provided
Not provided
To identify the most important barriers and facilitators to the participation of cisgender women living with HIV in clinical trials (perceived and real) and to establish possible mechanisms leading to refusal of trial participation. Specifically, psychosocial factors and/or cultural environments that enhance or undermine HIV-positive cisgender women's participation. These can include social inclusion, confidence in research, perceived personal vulnerability, cultural, familial and professional environment.
The investigators expect to propose pragmatic solutions to enhance participation of HIV-positive cisgender women in clinical trials.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Women living with HIV |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| no intervention | Other | qualitative study |
|
| Measure | Description | Time Frame |
|---|---|---|
| Evaluation of barriers and facilitators to the participation of women in clinical trials (HIV) through a questionnaire | Specific questions will be asked during a face-to-face interview to identify factors favoring or barriers to the participation of women in clinical trials. | through study completion, an average of 1 year |
| Evaluation of mechanisms leading to refusal of trial participation through a questionnaire | Specific questions will be asked during a face-to-face interview to understand mechanisms leading to refusal of trial participation. Specifically, psychosocial factors and/or cultural environments that enhance or undermine HIV-positive cisgender women's participation. These can include social inclusion, confidence in research, perceived personal vulnerability, cultural, familial and professional environment. | through study completion, an average of 1 year |
| Measure | Description | Time Frame |
|---|---|---|
| Offering solutions for a better inclusion of HIV-women in clinical trials - qualitative study | Analysis of questionnaires allowing recommendations to be made | through study completion, an average of 1 year |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Women living with HIV
Note: ethnicity will not represent a selection's criteria. However, special care will be payed to assure a certain heterogeneity in the sample concerning this aspect.
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Hôpitaux Universitaires de Genève | Geneva | 1205 | Switzerland |
Not provided
Not provided
Not provided
Not provided
Not provided
| Type | Date | Date Unknown |
|---|---|---|
| Release | May 8, 2024 | |
| Reset | Sep 17, 2024 | |
| Release | Dec 4, 2024 | |
| Reset | Jan 22, 2025 |
Not provided
Not provided
| Release Date | Unrelease Date | Unrelease Date Unknown | Reset Date | MCP Release Number |
|---|---|---|---|---|
| May 8, 2024 | Sep 17, 2024 | |||
| Dec 4, 2024 |
Not provided
Not provided
Not provided
| Jan 22, 2025 |